Atorvastatin Downregulates In Vitro Methyl Methanesulfonate and Cyclophosphamide Alkylation-Mediated Cellular and DNA Injuries

Table 2

Effects of atorvastatin after cotreatment with alkylating agents on Salmonella enterica typhimurium strains TA1535 and TA100.

Atorvastatin; (μM)		Cotreatment	TA1535		TA100
			His^+	MI	% reduction	His^+	MI	% reduction
—	−S9	DMSO 1%		1.00	—		1.00	—
0	−S9	MMS; (100 μM)		2.84	0.00		2.14	0.00
20	−S9			2.00	45.65		2.04	7.14
100	−S9			1.60	67.39		1.98	12.5
200	−S9			1.24	86.95		1.90	19.64
1000	−S9			1.16	91.30		1.86	23.21
—	+S9	DMSO 1%		1.00	—		1.00	—
0	+S9	CPA; (150 μM)		2.80	0.00		2.13	0.00
20	+S9			2.63	9.44		2.10	2.65
100	+S9			2.60	11.11		2.06	6.19
200	+S9			2.25	30.56		2.00	11.50
1000	+S9			2.04	42.22		1.93	17.70

MMS: methyl methanesulfonate; CPA: cyclophosphamide; His⁺: revertant colonies; MI: mutagenicity index. versus only MMS or only CPA (one-way ANOVA followed by a Dunnett’s post hoc test).